Related Experiment Video
Updated: May 16, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Identification of miR-30d as a novel prognostic maker of prostate cancer
Naohito Kobayashi1, Hiroji Uemura, Kiyotaka Nagahama
1Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Abstract:
Prostate cancer (PCa) is the most common malignant carcinoma that develops in men in Western countries. MicroRNA (miRNA) have the potential to be used as biomarkers and therapeutic targets for the treatment of various cancers. We found significantly higher expression of miR-30d in 3 PCa cell lines (PC3, DU145 and LNCaP) compared with 2 normal prostate cell lines (RWPE-1 and PrSc) using miRNA microarrays and qPCR. Clinicopathological study revealed that miR-30d expression levels were significantly higher in cancer tissue samples than in the paired normal controls (P = 0.03). Furthermore, the miR-30d-high group had shorter time to biochemical recurrence (P = 0.026). MiR-30d overexpressed PCa cells promoted proliferation and invasion in vitro. Inoculation of miR-30d depleted PCa cells dramatically reduced tumor volumes in vivo. Using reporter gene assay, we identified miR-30d as a downregulator of SOCS1 expression by directly binding to 3'-UTR of SOCS1. MiR-30d regulated the expression of phospho-STAT3, MMP-2 and MMP-9 through the downregulation of SOCS1. The levels of SOCS1 mRNA and protein were significantly down-regulated in prostate cancer tissues. Consistently, miR-30d expression was inversely correlated with SOCS1 expression (P = 0.03). The miR-30d-high/SOCS1-low group was associated with an increased risk of early biochemical recurrence (P = 0.0057). Taken together, miR-30d appears to be a novel independent prognostic marker of PCa progression that allows clinicians to identify patients who need more intensive treatments.
Insights
MicroRNA-30d (miR-30d) is highly expressed in prostate cancer (PCa) and promotes tumor growth and invasion. Elevated miR-30d levels correlate with poorer prognosis, identifying it as a potential biomarker for PCa progression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer (PCa) is a leading cause of cancer-related mortality in men.
- MicroRNAs (miRNAs) are emerging as critical regulators in cancer development and progression.
- Dysregulation of specific miRNAs can serve as diagnostic and prognostic indicators for various cancers.
Purpose of the Study:
- To investigate the role of miR-30d in prostate cancer.
- To determine the correlation between miR-30d expression and clinicopathological features of PCa.
- To identify the molecular targets and downstream pathways regulated by miR-30d in PCa.
Main Methods:
- Quantitative real-time PCR (qPCR) and miRNA microarrays were used to assess miR-30d expression.
- In vitro assays (proliferation, invasion) and in vivo xenograft models were employed to evaluate the functional role of miR-30d.
- Reporter gene assays and Western blotting were utilized to identify miR-30d targets and signaling pathways.
Main Results:
- miR-30d expression was significantly upregulated in PCa cell lines and tissues compared to normal controls.
- Overexpression of miR-30d promoted PCa cell proliferation and invasion in vitro and tumor growth in vivo.
- miR-30d directly targets SOCS1, leading to the downregulation of STAT3, MMP-2, and MMP-9.
- Lower SOCS1 expression was observed in PCa tissues and inversely correlated with miR-30d levels.
- High miR-30d/low SOCS1 expression was associated with increased risk of early biochemical recurrence.
Conclusions:
- miR-30d is a novel, independent prognostic biomarker for prostate cancer progression.
- miR-30d promotes PCa progression by downregulating SOCS1 and activating downstream signaling pathways.
- Targeting miR-30d may offer a potential therapeutic strategy for aggressive prostate cancer.
